Mannheim, Germany
Serox GmbH, a pioneering force in the biotechnology sector, has been offering cutting-edge solutions since its inception in 2006. Based in Germany, this startup stands out with its ability to synthesize customer-specific peptides, incorporating complex modifications such as phosphorylation and glycosylation, and distinguishing itself by providing peptides at various scales—from milligrams to kilograms.
Specializing in manufacturing, medical devices, and retail, Serox GmbH caters to diverse industry needs. Their expertise spans a wide range of peptide syntheses, including lipopeptides and peptide libraries, thus reaffirming their commitment to offering tailored solutions.
Despite their extensive track record, the company has not disclosed any recent investment activities, leaving potential investors the opportunity to engage with a well-established entity in a lucrative growth phase. For venture capitalists, Serox GmbH represents a robust prospect in a dynamic industry poised for exponential growth.
